SCHEMBL3565992

SCHEMBL3565992

O=C(O)c1ccc(OCCOc2ccccc2NS(=O)(=O)c2ccccc2F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.50
PTK2B Q14289 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
TSHR P16473 1/20 0.47
RAD52 P43351 1/20 0.47
KAT6A Q92794 4/20 0.46
ACLY P53396 3/20 0.44
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
FABP4 P15090 1/20 0.43
HRH2 P25021 1/20 0.42
HRH1 P35367 1/20 0.42
CACNA1H O95180 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3552423 0.90 PIK3CA (0.50) PKMPTK2BSMN1; SMN2RAD52KAT6A
SCHEMBL3553928 0.89 PKM (0.50) PKMPTK2BSMN1; SMN2MEN1NPC1
SCHEMBL3556624 0.88 ALDH1A1 (0.51) PKMPTK2BSMN1; SMN2MEN1NPC1
SCHEMBL3555144 0.86 PTK2B (0.57) PKMPTK2BMEN1NPC1RAB9A
SCHEMBL3563709 0.86 MEN1 (0.57) PKMMEN1KMT2ARAD52
SCHEMBL3558810 0.86 MRGPRX1 (0.51) PKMPTK2BSMN1; SMN2MEN1KMT2A
SCHEMBL3561665 0.85 CACNA1H (0.58) PKMMEN1KMT2ACACNA1HCACNA1B
SCHEMBL3550518 0.85 AR (0.53) PKMSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3554494 0.85 PKM (0.56) PKMSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL3554984 0.85 PKM (0.56) PKMNPC1CACNA1HCACNA1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 PKM 990/4885PTK2B 3187/4885SMN1; SMN2 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.